Objective
Alzheimer’s disease (AD) is the most common neurodegenerative disease and accounts for the majority of diagnosed dementia after age 60. It is estimated to currently affect between 20 and 30 million people worldwide, with 4 millions in the U.S. alone. As life expectancy increases in developed countries, the prevalence of AD, and its burden on healthcare, is very likely to increase dramatically in the next few decades. While waiting for a cure for AD as its prevalence will increase drastically over the years, a medication approach that would delay the onset of the disease would have a major impact of the disease incidence and prevalence, and thus on its burden on the economy of industrialized countries. Our main hypothesis is that excessive inflammatory processes (and its subsequent effect on protein function like MMPs and neurogenesis) are part of the early events triggering deleterious processes observed in AD later on. We do hypothesize that a diminution (but not complete inhibition) of those inflammatory processes, notably using the EC system, could benefit brain functions (neurogenesis, memory processes, APP processing to non-toxic amyloid forms…) and thus decrease the incidence of AD by delaying/reducing the appearance of hallmarks of AD. This proposal will then clarify the possible influence in vivo of chronic inflammation and its pharmacological modulation (and inflammatory-related proteases as MMPS), as well as neurogenic processes and behavior in a well-established transgenic model of AD. This study will thus provide valuable mechanistic information underlying the possible modulating role of the inflammation, MMPs and EC in the development of the AD pathology. Overall, those experiments could pave the way to a possible active treatment aiming at lowering the incidence of AD.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine neurology dementia alzheimer
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences basic medicine pathology
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-PEOPLE-2009-RG
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
13284 Marseille
France
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.